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Abstract
Background
The Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets require that,
by 2020, 90% of those living with HIV know their status, 90% of known HIV-positive individu-
als receive sustained antiretroviral therapy (ART), and 90% of individuals on ART have
durable viral suppression. The HPTN 071 (PopART) trial is measuring the impact of a uni-
versal testing and treatment intervention on population-level HIV incidence in 21 urban
communities in Zambia and South Africa. We report observational data from four communi-
ties in Zambia to assess progress towards the UNAIDS targets after 1 y of the PopART
intervention.
Methods and findings
The PopART intervention comprises annual rounds of home-based HIV testing delivered by
community HIV-care providers (CHiPs) who also support linkage to care, ART retention,
and other services. Data from four communities in Zambia receiving the full intervention
(including immediate ART for all individuals with HIV) were used to determine proportions of
participants who knew their HIV status after the CHiP visit; proportions linking to care and
initiating ART following referral; and overall proportions of HIV-infected individuals who
knew their status (first 90 target) and the proportion of these on ART (second 90 target),
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pre- and post-intervention. We are not able to assess progress towards the third 90 target at
this stage of the study. Overall, 121,130 adults (59,283 men and 61,847 women) were enu-
merated in 46,714 households during the first annual round (December 2013 to June 2015).
Of the 45,399 (77%) men and 55,703 (90%) women consenting to the intervention, 80% of
men and 85% of women knew their HIV status after the CHiP visit. Of 6,197 HIV-positive
adults referred by CHiPs, 42% (95% CI: 40%–43%) initiated ART within 6 mo and 53%
(95% CI: 52%–55%) within 12 mo. In the entire population, the estimated proportion of HIV-
positive adults who knew their status increased from 52% to 78% for men and from 56%
to 87% for women. The estimated proportion of known HIV-positive individuals on ART
increased overall from 54% after the CHiP visit to 74% by the end of the round for men and
from 53% to 73% for women. The estimated overall proportion of HIV-positive adults on
ART, irrespective of whether they knew their status, increased from 44% to 61%, compared
with the 81% target (the product of the first two 90 targets). Coverage was lower among
young men and women than in older age groups. The main limitation of the study was the
need for assumptions concerning knowledge of HIV status and ART coverage among adults
not consenting to the intervention or HIV testing, although our conclusions were robust in
sensitivity analyses.
Conclusions
In this analysis, acceptance of HIV testing among those consenting to the intervention was
high, although linkage to care and ART initiation took longer than expected. Knowledge of
HIV-positive status increased steeply after 1 y, almost attaining the first 90 target in women
and approaching it in men. The second 90 target was more challenging, with approximately
three-quarters of known HIV-positive individuals on ART by the end of the annual round.
Achieving higher test uptake in men and more rapid linkage to care will be key objectives
during the second annual round of the intervention.
Trial registration
ClinicalTrials.gov NCT01900977
Author summary
Why was this study done?
• Epidemiological and modelling studies have shown that universal testing and treatment
(UTT) for HIV, whereby everyone in the community should know their HIV status and
all HIV-infected individuals should be offered immediate antiretroviral therapy (ART),
may steeply reduce the incidence of new HIV infections in generalised epidemics in
sub-Saharan Africa.
• However, it is not known if such UTT interventions can be implemented on a large
scale in resource-poor settings, or what coverage can be achieved in practice.
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What did the researchers do and find?
• We are carrying out a large community-randomised trial, the HPTN 071 (PopART)
trial, to measure the impact of a UTT intervention on HIV incidence at the population
level over three years in 21 urban communities in Zambia and South Africa.
• We report here on the uptake of the intervention achieved in four Zambian communi-
ties after the first annual round of the intervention, which is delivered house-to-house
by trained lay health workers.
• Uptake of HIV testing with the lay health workers was high, and we found that after one
year, an estimated 78% of men and 87% women who were HIV-positive knew their
HIV status. Among known HIV-positive adults, around 73% were on ART by the end
of the annual round.
• The estimated overall proportion of HIV-positive adults on ART, irrespective of
whether they knew their status, increased from 44% to 61% following the intervention.
• The main challenges were that many men could not be contacted during home visits,
that linkage to care and initiation of ART were slower than anticipated, and that overall
coverage was lower in young people.
What do these findings mean?
• The Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets
require that, by 2020, 90% of HIV-positive individuals know their status (first 90 target),
90% of known HIV-positive individuals are on ART (second 90 target), and 90% of
those have durable viral suppression (third 90 target).
• We have shown that after the first annual round of a community-wide household-based
intervention, knowledge of HIV-positive status was close to the first 90 target in
women, and approaching it in men. There was a substantial increase in the proportion
of known HIV-positive individuals on ART, although the second 90 target has not yet
been reached.
• The repeated annual rounds of household visits are a strength of the PopART interven-
tion, and, based on the findings of the current analysis, future rounds will focus on key
challenges, including reaching men and young people and achieving more rapid linkage
to care and ART initiation.
Introduction
While there have been some reductions globally in the incidence of new HIV infections, inci-
dence and prevalence remain at unacceptably high levels in many parts of sub-Saharan Africa.
This is especially the case in southern Africa, where many regions are still experiencing severe
generalised epidemics. Thanks to the large-scale rollout of antiretroviral therapy (ART), mor-
tality from HIV has fallen [1]. HIV incidence has not fallen to the same extent, however, and
the number of new HIV infections each year exceeds the number of deaths, meaning that the
total number of HIV-infected individuals continues to increase [1]. Unless effective ways can
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be found of steeply reducing incidence, it will become increasingly difficult to sustain ART ser-
vices for all who need them.
Wide-scale provision of ART is now recognised as a key preventive intervention for HIV
control. The concept of treatment as prevention is based on evidence showing that HIV trans-
mission is strongly correlated with viral load, and that the risk of transmission is very low if
virus is undetectable [2–5]. The HPTN 052 trial showed definitively that early initiation of
ART reduced HIV transmission by an estimated 96% [3]. Mathematical modelling has shown
that if a large enough proportion of the HIV-positive population is diagnosed and started on
treatment, with good enough retention and adherence to achieve high rates of viral suppres-
sion, this could lead to steep reductions in HIV incidence and potentially to the long-term
elimination of HIV as a public health problem [6–9]. Observational data from a range of set-
tings have demonstrated correlations between ART coverage at the population level and
reductions in HIV incidence [10–14].
Based on this evidence, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has
promulgated a set of targets aimed at ensuring that a high proportion of the HIV-infected pop-
ulation is diagnosed, on ART, and virally suppressed, with the aim of reducing HIV incidence
as well as protecting the health of HIV-infected individuals [15,16]. The 90-90-90 targets are to
be achieved by 2020 and require that 90% of all people living with HIV know their status, that
90% of all people diagnosed with HIV receive sustained ART, and that 90% of all people receiv-
ing ART have durable viral suppression [15]. Taken together, meeting these targets would
imply that approximately 73% of HIV-infected individuals would be virally suppressed. An
even more ambitious set of 95-95-95 targets is to be achieved by 2030, with the aim of substan-
tially reducing HIV incidence and prevalence by then [16].
While it may be useful to have aspirational targets for service coverage, it is not known
whether such targets can be achieved on a large scale at the population level, or what are the
most effective and cost-effective methods of achieving them. Changes to WHO guidelines to
recommend immediate initiation of ART for all people living with HIV, irrespective of CD4
count, will remove one barrier to achieving the second 90 target. However, there are many
other obstacles and challenges to ensuring universal testing and treatment (UTT), including
the need to scale up HIV testing in the community so that everyone knows their current HIV
status, and the need to ensure that all HIV-infected individuals are linked to care and com-
mence ART rapidly, with high rates of retention, adherence, and viral suppression.
The HPTN 071 (PopART) trial is implementing a combination prevention programme in
Zambia and South Africa aiming to achieve UTT through a house-to-house service delivered
by a cadre of community health workers, and to measure its effectiveness and cost-effective-
ness in reducing HIV incidence at the population level [17]. In this paper, we examine findings
from the trial communities receiving the PopART UTT intervention in Zambia after the first
year of the intervention. We examine what coverage has been achieved following the first
annual round, what difference this has made to key indicators of uptake, and how close we
have come to the first two of the 90-90-90 targets, which are important process outcomes for
the trial. We also ask what are the most important barriers to meeting these targets. The impact
of the PopART intervention on the primary outcome (HIV incidence) will be reported follow-
ing trial completion in 2018.
Methods
Trial design
Full details of the HPTN 071 (PopART) trial and intervention have been presented previously
[17]. In brief (Fig 1), 21 urban and peri-urban communities in Zambia and South Africa (each
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community defined as the catchment population of a government health facility at which ser-
vices for HIV care and ART provision were already in place) were formed into seven matched
triplets (four in Zambia and three in South Africa) and randomly allocated to three study
arms. Arm A is receiving the full PopART intervention including immediate ART irrespective
of CD4 count. Arm B is receiving the full intervention except that ART is provided according
to current national treatment guidelines. Arm C is a control arm, which continues to receive
existing standard of care including ART according to current national treatment guidelines.
To measure the impact of the intervention, a population cohort comprising a random sam-
ple of adults aged 18–44 y (approximately 2,000 per community) has been enrolled. Following
a baseline survey, the cohort will be followed up at annual intervals for 3 y. The primary objec-
tive of the trial is to measure the population-level impact of the intervention by comparing
HIV incidence over 36 mo between the three study arms.
Here we report data on the uptake and coverage of the UTT intervention after the first
annual round of intervention in the entire population of our Arm A communities in Zambia.
During the first annual round, some challenges were encountered in the collection of interven-
tion data from our South African communities. In particular, there was some under-recording
of community members who were absent or declined to participate in the intervention or who
declined an HIV test. These problems have since been resolved, and we plan to report uptake
and coverage in South Africa during later rounds of intervention in due course.
Fig 1. Overview of design of the HPTN 071 (PopART) trial. ART, antiretroviral therapy; TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002292.g001
Findings from Zambia after one year of the PopART universal testing and treatment intervention
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002292 May 2, 2017 5 / 22
Intervention
The PopART intervention is a combination prevention package with several components. A
cadre of community HIV-care providers (CHiPs) provides house-to-house services for all mem-
bers of the community, including annual HIV testing and counselling; linkage to care at the local
government health facility and support for adherence and retention in care for those identified
as HIV-positive; promotion of voluntary medical male circumcision (VMMC) for HIV-negative
uncircumcised men and referral to local VMMC services; promotion of prevention of mother-
to-child transmission (PMTCT) services for pregnant women; referral of those reporting symp-
toms of sexually transmitted infections for diagnosis and treatment at the health facility; screen-
ing for symptoms of tuberculosis (TB) and linkage to care for those diagnosed with TB; and
promotion and provision of condoms. ART is provided as a routine service by the health facility.
CHiPs work in pairs, with each pair serving a zone consisting of around 500 households.
They visit all households in their zone to provide annual testing and re-testing using HIV
rapid tests, as well as making additional visits as necessary to complete intervention provision
and follow-up. They record basic data on the household and all household members on an
electronic data capture (EDC) device, with more detailed data (e.g., on HIV test history, ART
status, and uptake of HIV testing and other services provided by CHiPs) recorded for adults
aged 18 y and above who consent to receive the intervention. The EDC populates a CHiP data-
base, which is used to obtain process measures on the uptake of the intervention. There is no
fixed schedule for follow-up visits during the annual round, but special efforts are made to fol-
low up all participants known to be HIV-positive to support them to link to and stay in HIV
care, as well as to record information on these outcomes.
The PopART intervention will be delivered in four annual rounds. In this paper, we report
the outcome of the first annual round (delivered from December 2013 to June 2015, with some
variation as to when services were rolled out in communities) in the four Arm A communities
in Zambia, to determine how close a UTT intervention can come to meeting the first two of
the 90-90-90 targets after a single year of intervention. While services including testing and
linkage to care are offered for all household members, ethical approval for data collection dur-
ing the first annual round was obtained only for adults aged 18 y and over, and so analyses are
restricted to this age group.
Statistical methods
The statistical analysis plan for the parent HPTN 071 (PopART) study is currently under
development and review, and had not been finalised at the time that the process data analysis
reported in this paper was carried out. The indicators of intervention coverage used for the
current analyses were determined at the start of the trial, but when the UNAIDS 90-90-90 tar-
gets were announced at a later stage (September 2014), our analyses were extended to provide
estimates of coverage against these targets.
Data from the CHiP database were first used to populate a cascade of care diagram showing
the proportions completing each step required if individuals are to know their HIV status and
initiate ART. Separate estimates were obtained for men and women, and the data were pooled
across all four communities in Arm A. First, we calculated the proportion of households visited
during the first annual round, with the denominator (number of households) obtained from a
census carried out prior to the trial, and, second, we calculated the proportion of visited house-
holds that consented both to the intervention being explained and to enumeration (listing) of
all household members on the EDC device. Third, we calculated the proportion of enumerated
adult members who were contacted and consented to take part in the PopART intervention
and, of these, the proportion who knew their HIV status following the CHiP visit because they
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accepted the offer of an HIV test from the CHiP, self-reported as HIV-positive, or self-reported
as HIV-negative based on a test within the previous 3 mo. Fourth, we computed the number
and proportion of “known HIV-positive” adults who were referred to care by the CHiP, overall
and with restriction to those who had never previously registered for HIV care. Finally, we
computed the proportion of those referred who had linked to care and commenced ART by 6
mo and 12 mo after referral by a CHiP. Because individuals were referred at different times,
with differing durations of follow-up, these proportions were estimated by Kaplan–Meier
“time to event” analysis, using retrospective information from follow-up visits by CHiPs up to
mid-2016 but with follow-up right-censored at the end of the first annual round (30 June
2015). The corresponding survival plots were obtained from the same analysis.
This cascade of care focuses on the success of the intervention in contacting adults, achieving
high rates of participation among those contacted, achieving high rates of test uptake among
those who consent to participate, and linking to care those HIV-positive adults who are not
already on ART. We carried out further analyses to obtain a more complete picture of the overall
proportion of adults who knew their HIV status, the overall proportion known to be HIV-posi-
tive, and the proportion of known HIV-positive adults who were in HIV care or on ART prior to
the intervention, and to determine how much these proportions were increased by the interven-
tion. Using the CHiP database, among those consenting to the PopART intervention, we com-
puted the proportion who knew their HIV status (and the proportion known to be HIV-positive)
among all adults, before and after the CHiP visit. Taking those who were known HIV-positive
after the CHiP visit as the denominator, we then computed the proportions in care and on ART
at the time of the CHiP visit, as well as at the end of the first annual round of intervention (using
as the denominator those still resident in the same zone of the community according to the most
recent follow-up information, based on follow-up data collected on or before 30 June 2015).
Finally, we used these data to estimate coverage against the first two of the 90-90-90 targets:
proportion of individuals with knowledge of HIV-positive status and proportion of known
HIV-positive individuals on ART. All calculations were stratified by sex, community, and age
group. Full details of the computations of these estimates are given in S1–S4 Tables, illustrated
using data for women in one age group. We present coverage estimates separately for men and
women of all ages, and also by age group.
We first estimated coverage among all adults who consented to the PopART intervention.
To estimate the proportion of HIV-positive individuals who knew their status before and after
the CHiP visit, we assumed, first, that all those who knew they were HIV-positive self-reported
this to the CHiP and, second, that among those whose HIV status was not known to the CHiP
(because they declined to test with the CHiP and did not self-report that they were HIV-posi-
tive or that they had tested HIV-negative within the previous 3 mo), the HIV prevalence
was the same as among those who accepted a test (Assumption A). Coverage against the first
90 target was estimated before and immediately after the CHiP visit, using data on HIV test
uptake and results. Coverage against the second 90 target, based on those self-reporting that
they were in HIV care or currently on ART among those known HIV-positive, was estimated
before and immediately after the CHiP visit, and also at the end of the first annual round to
take account of participants newly initiated on ART after the CHiP visit.
To estimate overall coverage against the first two 90 targets in the entire adult population of
these communities, some additional assumptions were needed. This was because no data were
available for households that did not consent to enumeration of household members and
because, among households that consented to enumeration, the only information available for
adults who did not consent to participate was their age and sex. We assumed, first, that HIV
prevalence was the same in those consenting and not consenting to the intervention (Assump-
tion B); second, that the proportion of HIV-positive individuals who knew their HIV status
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prior to the CHiP intervention was the same in those consenting and not consenting (Assump-
tion C); and, third, that the proportions of known HIV-positive individuals in care or on
ART prior to the CHiP intervention were the same in those consenting and not consenting
(Assumption D). All of the above assumptions (A to D) were assumed to apply within strata
defined by sex, community, and age group.
We conducted two further analyses to explore the sensitivity of the above coverage esti-
mates to the assumptions made. First, for each assumption (A to D), we assumed that the true
proportion was equal to the assumed value or was increased or decreased by a factor of 1.25.
We examined the range of coverage estimates resulting from these 81 (34) combinations of
values, and provide the minimum and maximum values together with the central estimate.
Second, we made alternative assumptions about adults whose HIV status was not known to
CHiPs: these alternative assumptions were that HIV prevalence was twice as high as among
those who tested with the CHiPs, that the percentage who knew their HIV-positive status was
the same as in those whose HIV status was known to CHiPs, and that ART uptake among
those who knew their HIV-positive status was either the same or half the value as among those
who self-reported as HIV-positive to the CHiPs.
Laboratory methods
CHiP participants were initially screened for HIV infection by fingerprick using the Alere
Determine HIV-1/2 test (Alere International). Participants with a non-reactive test had no fur-
ther testing. Participants with reactive results were further tested with the Uni-Gold HIV test
(Trinity Biotech). If results were concordant, the participant was referred for care. If results
were discordant, the testing was repeated. If the results were still discordant, the CHiPs would
return 2 wk later for follow-up testing. If results were discordant again, a venous blood sample
was collected and sent to the laboratory for further testing using the rapid tests and, if indi-
cated, testing using the Abbott Architect HIV Ag/Ab Combo Assay. This test algorithm is in
keeping with Zambian national guidelines.
Ethical considerations
During CHiP visits to households, all adults were asked for verbal informed consent to take
part in the PopART intervention, which included the collection of data on the CHiP EDC.
Those agreeing to a rapid HIV test gave written consent according to standard health care pro-
cedures for HIV testing and counselling in Zambia. The study and all the above procedures
were approved by the ethics committees of the London School of Hygiene & Tropical Medi-
cine and the University of Zambia.
Results
Cascade of care
A total of 48,583 households were visited during the first annual round in the four study com-
munities in Zambia, close to 100% of all households listed during the community census prior
to the study. Enumeration of individual household members was completed in 46,714 (96%)
of the households visited, with a total of 121,130 adults aged 18 y and over (59,283 men and
61,847 women) (Fig 2). Of those enumerated, 77% of men and 90% of women consented to
the PopART intervention. Of those consenting, 80% of men and 85% of women knew their
HIV test status following the CHiP visit, because they self-reported that they were HIV-posi-
tive, because they accepted the offer of an HIV rapid test by the CHiP, or because they self-
reported that they had tested HIV-negative in the previous 3 mo.
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Following the CHiP visit, a total of 4,138 men and 8,702 women were known to be HIV-pos-
itive, representing 11% and 18% of those who knew their HIV status among men and women,
respectively. Of these, 2,133 men and 4,765 women reported that they were already in HIV care,
and 1,941 and 4,308, respectively, were on ART. Among those not on ART, CHiPs referred a
total of 2,053 men and 4,144 women to the local government health facility, including 5,783/
5,847 (99%) of those reporting that they had never previously registered for HIV care.
Among the total of 6,197 adults who were not on ART at the time of the first household
visit and were referred to HIV care, 42% (95% CI: 40%–43%) had initiated ART within 6 mo
and 53% (95% CI: 52%–55%) within 12 mo, with very similar rates in men and women. Fig 3
shows survival plots for time from referral to linkage to care and ART initiation and indicates
that by 3 mo only 41% (95% CI: 40%–42%) had linked to care and 32% (95% CI: 31%–33%)
had initiated ART, but with additional individuals linking to care and starting ART each
month up to at least 1 y.
Change in knowledge of HIV status and linkage to care following
intervention
At the time of the CHiP visit, 18% of men and 26% of women who consented to the interven-
tion self-reported that they were HIV-positive or that they had tested HIV-negative in the
Fig 2. Cascade of care from enumeration of household members through ART initiation during the first annual round of the PopART intervention.
ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pmed.1002292.g002
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previous 3 mo and thus knew their current HIV test status (Table 1). After the CHiP visit, as a
result of the HIV tests provided by the CHiPs, the proportion who knew their current test sta-
tus increased to 80% and 85%, respectively.
Fig 3. Time from referral to linkage to care and ART initiation during the first annual round of the PopART intervention. Survival curves showing
cumulative proportions linking to care or initiating ART following referral by community HIV-care providers. ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pmed.1002292.g003
Table 1. Change in knowledge of HIV status, linkage to care, and ART uptake following the intervention among men and women.
Indicator Before or after Round 1 CHiP visit Men Women
n/N Percent n/N Percent
Knows HIV status/all who consented Before1 8,305/45,399 18% 14,558/55,703 26%
After2 36,398/45,399 80% 47,089/55,703 85%
Known HIV-positive/all who consented Before1 2,423/45,399 5% 5,309/55,703 10%
After2 4,138/45,399 9% 8,702/55,703 16%
In HIV care/all known HIV-positive Before2 2,133/4,138 52% 4,765/8,702 55%
After3 2,506/3,222 78% 5,528/7,043 78%
On ART/all known HIV-positive Before2 1,941/4,138 47% 4,308/8,702 49%
After3 2,309/3,222 72% 5,106/7,043 72%
1Prior to annual round visit.
2Immediately following annual round visit.
3At end of Round 1 (restricted to adults still resident in the same zone of the community at end of Round 1 according to last recorded information from
Round 1).
ART, antiretroviral therapy; CHiP, community HIV-care provider.
https://doi.org/10.1371/journal.pmed.1002292.t001
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Of the 4,138 men and 8,702 women known to be HIV-positive after the CHiP visit, 52% of
men and 55% of women were already in HIV care, while 47% of men and 49% of women were
already on ART. At the end of the first annual round, 3,222/4,138 (78%) of the known HIV-
positive men and 7,043/8,702 (81%) of the known HIV-positive women were still resident in
the same zone of the community according to the last available information. By the end of the
first annual round of the intervention, the proportions of both men and women in care and on
ART had increased to 78% and 72%, respectively.
Reaching the 90-90-90 targets
Data on knowledge of HIV-positive status and linkage to care were used to estimate coverage
against the first two of the 90-90-90 targets at three time points, before and immediately after
the CHiP visit and at the end of the first annual round of the intervention (Tables 2 and 3).
These estimates were obtained based on the assumptions described in the Methods.
Table 2. Estimated proportions of HIV+ individuals who knew their status and who were on ART before the CHiP visit, immediately after the CHiP
visit, and at the end of Round 1, in those consenting to the intervention.
Indicator Before CHiP visit Immediately after CHiP visit End Round 11
Men
Number HIV+ among those who consented to participate in Round 1 (estimated) 4,662 4,662 3,630
Number (percent) who know HIV+ status 2,423 (52%) 4,138 (89%) 3,222 (89%)
Number (percent) on ART 1,941 (80%) 1,941 (47%) 2,309 (72%)
Overall proportion on ART 42% 42% 64%
Women
Number HIV+ among those who consented to participate in Round 1 (estimated) 9,499 9,499 7,688
Number (percent) who know HIV+ status 5,309 (56%) 8,702 (92%) 7,043 (92%)
Number (percent) on ART 4,308 (81%) 4,308 (49%) 5,106 (72%)
Overall proportion on ART 45% 45% 66%
1End Round 1 numbers and percentages are restricted to adults still resident in the same zone of the community at the end of Round 1, according to the
most recently available information.
ART, antiretroviral therapy; CHiP, community HIV-care provider.
https://doi.org/10.1371/journal.pmed.1002292.t002
Table 3. Estimated proportions of HIV+ individuals who knew their status and who were on ART before the CHiP visit, immediately after the CHiP
visit, and at the end of Round 1, in total adult population.
Indicator Before CHiP visit Immediately after CHiP visit End Round 11
Men
Number HIV+ among total adult population in Round 1 (estimated) 6,649 6,649 5,206
Number (percent) who know HIV+ status 3,451 (52%) 5,166 (78%) 4,045 (78%)
Number (percent) on ART 2,769 (80%) 2,769 (54%) 2,975 (74%)
Overall proportion on ART 42% 42% 57%
Women
Number HIV+ among total adult population in Round 1 (estimated) 11,037 11,037 8,958
Number (percent) who know HIV+ status 6,197 (56%) 9,590 (87%) 7,784 (87%)
Number (percent) on ART 5,036 (81%) 5,036 (53%) 5,715 (73%)
Overall proportion on ART 46% 46% 64%
1End Round 1 numbers and percentages are restricted to adults still resident in the same zone of the community at the end of Round 1, according to the
most recently available information.
ART, antiretroviral therapy; CHiP, community HIV-care provider.
https://doi.org/10.1371/journal.pmed.1002292.t003
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Among those consenting to the intervention, we estimate that prior to the intervention 52%
of all HIV-positive men and 56% of all HIV-positive women knew their HIV-positive status.
After the first annual round, these proportions increased to 89% of men and 92% of women,
close to or exceeding the first 90 target (Fig 4).
Among those known HIV-positive prior to the CHiP visit, 80% of men and 81% of women
reported that they were currently on ART. Immediately after the CHiP visit, this proportion
decreased to 47% and 49% as a result of the increase in the denominator due to the large num-
ber of HIV-positive individuals newly diagnosed by the CHiPs. By the end of the annual
round, however, the proportion on ART had increased to 72% and 72% in men and women,
respectively.
Estimated coverage against the first two 90 targets in the entire adult population was some-
what lower because not everyone was enumerated or consented to the intervention. Based on
the stated assumptions, we estimate that the proportion of HIV-positive individuals who knew
their HIV-positive status increased from 52% of men and 56% of women before the interven-
tion to 78% and 87%, respectively, after the first annual round. The proportion of known HIV-
Fig 4. Estimated coverage compared with the first two 90 targets in those consenting to the PopART intervention. Dark blue bars show the estimated
proportion of HIV+ adults who knew their status (first 90 target) and the estimated proportion of those who knew their HIV+ status who were on ART (second
90 target), pre-intervention. Red bars show the same estimated proportions, post-intervention. ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pmed.1002292.g004
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positive individuals on ART increased from 54% of men and 53% of women immediately after
the CHiP visit to 74% and 73%, respectively, by the end of the annual round (Fig 5).
Table 2 also shows that the estimated overall proportion of HIV-positive adults on ART
increased from 42% to 57% in men and from 46% to 64% in women, compared with the target
of 81% based on the product of the first two of the 90-90-90 targets. S1 Fig shows an alternative
display of coverage against the targets, similar to that used to report the Agence Nationale de
Recherche sur le Sida et les He´patites Virales 12249 Treatment as Prevention trial (ANRS
12249 TasP trial) [18].
Fig 6 shows the coverage estimates for the first and second 90 targets broken down by age
group as well as sex. Prior to the CHiP intervention, knowledge of HIV-positive status and ART
coverage were considerably lower in young men and women than in older age groups. HIV test
uptake by young adults who participated in the intervention was high, so that by the end of the
first annual round, knowledge of HIV-positive status was close to 90% in all age groups. In the
entire population, estimated knowledge of HIV-positive status remained high among women,
Fig 5. Estimated coverage compared with the first two 90 targets extrapolated to the total adult population. The red line shows the 90% target for first
two of the 90-90-90 targets. Dark blue bars show the estimated proportion of HIV+ adults who knew their status (first 90 target) and the estimated proportion of
those who knew their HIV+ status who were on ART (second 90 target), pre-intervention. Red bars show the same estimated proportions, post-intervention.
ART, antiretroviral therapy.
https://doi.org/10.1371/journal.pmed.1002292.g005
Findings from Zambia after one year of the PopART universal testing and treatment intervention
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002292 May 2, 2017 13 / 22
but fell to around 70%–80% among young men because of the relatively large number who
could not be contacted by CHiPs during household visits (17%, 20%, 24%, and 26% of men
aged 18–19, 20–24, 25–29, and 30–34 y, respectively, were not contacted by CHiPs during
Round 1). In both men and women, by the end of the first annual round, ART coverage among
known HIV-positive individuals was relatively high in older age groups, at approximately 80%
among men40 y and women35 y, but remained lower (around 50%–60%) in the youngest
men and women. Fig 7 shows overall estimates of the proportion of HIV-positive adults on
ART by age group and sex. After the first annual round, these estimates were approaching the
81% target in older adults, but were considerably lower in young men and women.
Sensitivity analysis
S5 Table shows two sensitivity analyses for the estimates of coverage for the first and second 90
targets. Focusing on coverage after the first annual round of the intervention, estimates were
Fig 6. First two 90 target estimates by sex and age group in those consenting to the PopART intervention and extrapolated to the total adult
population. The red line shows the 90% target for first two of the 90-90-90 targets. The first 90 target is proportion of individuals with knowledge of HIV-
positive status, and the second 90 target is proportion of known HIV-positive individuals on antiretroviral therapy. CHiP, community HIV-care provider.
https://doi.org/10.1371/journal.pmed.1002292.g006
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not sensitive to assumptions about adults who consented to the intervention. The sensitivity
analyses produced a wider range of estimates when extrapolating to the entire adult popula-
tion, although qualitative conclusions were broadly similar, with higher knowledge of HIV-
positive status in women (82%–91%) than men (70%–84%) and with ART coverage among
known HIV-positive individuals between 69%–79% in both men and women.
Discussion
This study showed substantial increases in knowledge of HIV status and ART coverage after
the first annual round of a UTT intervention delivered through a home-based service linked to
government health facilities providing care and treatment for HIV. Among those consenting
to the intervention, knowledge of current HIV status increased from around 20% to greater
than 80%, while ART coverage among known HIV-positive individuals increased from around
50% to 70%. In the entire adult population, the estimated proportion of HIV-positive individu-
als who knew their status (first 90 target) increased from 52% to 78% in men and from 56% to
Fig 7. Overall estimates of proportion of HIV+ adults on ART by age group and sex in those consenting to the PopART intervention and
extrapolated to the total adult population. The red line shows the cumulative 81% target based on first two of the 90-90-90 targets. ART, antiretroviral
therapy; CHiP, community HIV-care provider.
https://doi.org/10.1371/journal.pmed.1002292.g007
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87% in women, while the proportion of known HIV-positive individuals on ART (second 90
target) increased from 54% after the CHiP visit to 74% by the end of the round in men and
from 53% to 73% in women. The estimated overall proportion of HIV-positive adults on ART,
irrespective of whether they knew their HIV status, increased from 44% to 61%, compared
with the 81% UNAIDS target for the first two 90 targets.
The concept of treatment as prevention has revitalised efforts to bring the HIV epidemic
under effective control. The rationale for the concept is strong, and if high coverage can be
achieved, the evidence suggests that the incidence of new infections should be reduced sub-
stantially. As a result, it now seems realistic to consider scenarios in which HIV prevalence and
incidence are reduced in the long term to low levels, such that HIV/AIDS no longer constitutes
a major public health problem.
These potential benefits will not be achieved, however, unless high rates of coverage can be
achieved and sustained. There is increasing recognition that this will be challenging, both
because of the many barriers to testing and care in settings with severe resource constraints
and because high uptake requires the long series of steps in the cascade of care to be success-
fully negotiated [19–22]. The 90-90-90 targets, if they can be achieved, imply that only 73% of
individuals living with HIV will be virally suppressed and therefore unlikely to transmit the
virus to others [15]. If coverage is reduced to 80% at each step, the proportion virally sup-
pressed falls to 51%. The problem is compounded because each of the 90-90-90 targets itself
involves multiple steps. For example, the first 90 target requires that an individual is offered a
test (at regular intervals), accepts the test, and receives the correct result. The second 90 target
requires that the individual is effectively linked to care, and then attends repeated clinic visits
until ART is prescribed and commenced. The third 90 target requires retention in care, high
adherence to ART, and a regimen that is effective in achieving viral suppression in that indi-
vidual. Seen in this light, the 90-90-90 targets will not be easy to achieve.
There have been relatively few attempts to estimate coverage against the targets on a large
scale in resource-poor settings in sub-Saharan Africa [23–28]. We have used data from the larg-
est ongoing programme to deliver UTT at the population level to provide such estimates. We
find that after one annual round of the PopART intervention in four large communities in
Zambia, we have come close to achieving the first 90 target in women and are approaching it in
men. The second 90 target has proven more challenging, and although we have increased the
estimated proportion of known HIV-infected individuals on ART from around 53% to 73%,
the coverage needs to be increased. Data on the third 90 target, relating to retention on ART
and viral suppression, will be obtained during the second annual round of the intervention.
Our findings agree with other studies in showing that a house-to-house service is able to
achieve high rates of testing and knowledge of HIV status among community members [29].
Detailed results on test uptake will be reported elsewhere, but indicate that coverage of HIV
testing is systematically higher among women than men. While men are only slightly more
likely than women to decline a test when it is offered by the CHiPs, a significant challenge is
that they are often not found at home during house-to-house visits. Reductions in the high
incidence of HIV among women, particularly young women, will be limited unless their male
partners are effectively tested, linked to care, and virally suppressed on ART [30]. Other studies
have also found poorer coverage among men with home-based testing, and have suggested
that additional testing strategies such as mobile or occupational testing facilities or self-testing
may be needed to achieve high coverage in this group [31].
As in other programmes, the time taken for those diagnosed HIV-positive to link to care
and commence ART has been longer than anticipated [19,32,33]. Our initial target was for
ART to be commenced in 80% of individuals within 3 mo of referral. In practice, we found
that slightly over 50% of both men and women commenced ART within 12 mo of referral.
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While the survival curves show that more and more individuals start ART over time, we need
to speed up the rates of linkage and commencement of ART, and this was identified as a major
focus of the CHiP intervention for the second annual round. Impact on HIV incidence will be
limited unless HIV-positive individuals can be linked to care and initiated on ART rapidly,
with lifelong retention and adherence to ART.
Of key importance were our findings on differential coverage across age groups. After the
first annual round of intervention, knowledge of HIV status was high across all age groups in
women and in older men, but was considerably lower among young men. Test uptake was
high among young men who consented to the intervention, but a relatively large number of
young men could not be contacted by CHiPs. ART coverage at the end of the first annual
round among known HIV-positive individuals was considerably lower in young men and
women than in older men and women, consistent with previous research [34]. Linkage to care
and initiation of ART among those referred by CHiPs were slightly slower among younger
adults, and far fewer young adults were already on ART at the start of the intervention, and
this depressed coverage for the second 90 target. These findings emphasise the importance of
contacting and engaging young men and women, and linking them to care as rapidly as possi-
ble. Full data on uptake by age and sex will be published separately.
Three other community-randomised trials in sub-Saharan Africa are measuring the impact
of UTT interventions on HIV incidence: the ANRS 12249 TasP trial in South Africa [18], the
Sustainable East Africa Research on Community Health (SEARCH) trial in Kenya and Uganda
[35], and the Botswana Combination Prevention Project (BCPP) trial in Botswana [26]. Re-
sults from the first of these, the ANRS 12249 TasP trial, have recently been reported [36]. In
this study in KwaZulu-Natal, South Africa, six-monthly home-based testing resulted in high
uptake of HIV testing among those contacted, and high rates of viral suppression 12 mo after
ART initiation. As in our study, linkage to care and ART initiation (at clinics provided by the
study) were slower than expected, with only 36% accessing care within 6 mo of referral. Analy-
sis of HIV incidence showed no evidence of impact. Importantly, however, the home-based
programme for HIV testing and linkage to care was delivered to both intervention and control
arms of the study, which differed only in the threshold for ART initiation. Overall coverage of
ART was similar in the two study arms, and so it is unsurprising that no impact on HIV inci-
dence was observed. In contrast, the HPTN 071 (PopART) trial will compare HIV incidence
in intervention communities receiving the full UTT intervention with that in control commu-
nities receiving current standard of care (not including home-based testing).
Our study has a number of limitations. Data on coverage are only collected on those who
participate in the CHiP intervention, and in order to obtain estimates for the entire adult popula-
tion, we had to make assumptions about those not participating. We also rely on self-report of
known HIV-positive status and whether individuals are in care or on ART, although documen-
tary evidence is sought where possible. Another limitation is that our estimates of coverage
ignore any new HIV seroconversions occurring between the initial annual round visit and the
end of the round, although these are likely to have only a small effect, given the average duration
of follow-up and expected HIV incidence. A further limitation is that data were collected only on
adults aged 18 y and over. Although these will encompass a large proportion of those with HIV
infection, we know that there is a continuing high incidence and prevalence in young people in
many settings. Following ethical review, we are now able to collect data on minors, subject to
parental consent, and so in future will be able to document uptake in this important age group.
Strengths of our study are that we have collected data systematically for most households
and a large proportion of adults in these large communities, and have stated our methods and
assumptions clearly. We have also carried out analyses to examine the sensitivity of our esti-
mates to the assumptions made. We believe that comparisons of coverage estimates between
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countries, settings, and programmes are susceptible to significant bias and distortion due to
different availability of data and assumptions made in the analyses, and some harmonisation
of such analyses is called for. The Universal Test and Treat Trials Consortium (UT3C), which
comprises investigators from five randomised trials of UTT interventions in sub-Saharan
Africa, is planning joint cross-study analyses to further explore this issue.
This paper reports uptake following the first year of the PopART intervention. A strength
of this intervention is that household visits are made to all households during each annual
round, as well as repeat visits during each year as appropriate. This approach offers the oppor-
tunity to continuously increase coverage, by accessing individuals who were previously not at
home, offering tests to those who initially declined testing, and making special efforts to
encourage linkage to care where this has not already occurred. After the first year, estimated
overall coverage against the first two 90 targets combined has increased from 44% to 61%, indi-
cating the gap still to be filled to reach the target of 81%. It will be important to document how
uptake evolves over time, and we plan to report this after the second annual round of the inter-
vention. The initial data, however, demonstrate that a community-wide intervention provided
through a house-to-house service in communities with severe generalised HIV epidemics may
be effective in achieving or approaching the 90-90-90 targets.
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